Activated Charcoal Antimony Trisulfide Arctium Lap

證據等級: L5

預測適應症: 0 個

Multi-Component Homeopathic Formula: Insufficient Data for Repurposing Evaluation

One-Sentence Summary

This entry represents a 24-ingredient homeopathic compound formula (including Activated Charcoal, Arsenic Trioxide, Berberis Aquifolium, Echinacea, and Nux Vomica, among others) with no regulatory registration in Taiwan or the United States. The TxGNN model returned no predicted indications for this compound, most likely because the multi-ingredient composition could not be mapped to a single DrugBank entity. Due to missing identity, indication, and safety data, a meaningful repurposing evaluation cannot be completed at this stage.

Quick Overview

Item	Content
Original Indication	Unknown — no regulatory approval on record
Predicted New Indication	None — TxGNN returned no predictions
TxGNN Prediction Score	N/A
Evidence Level	L5 (model-pipeline failure; no studies identified)
Market Status	Not marketed (Taiwan)
Number of Approvals	0
Recommended Decision	Hold

Why No Prediction Was Generated

The TxGNN pipeline requires a valid DrugBank ID to anchor the compound in the knowledge graph and generate disease–drug link scores. This formulation contains 24 distinct ingredients (spanning mineral salts, plant extracts, and homeopathic dilutions) and was submitted as a single combined string. As a result:

DrugBank mapping failed — no single DrugBank ID could be assigned, so the knowledge-graph embedding step could not proceed.
Disease mapping could not be initiated — without a known original indication or approved use, the model has no anchor disease node from which to project repurposing candidates.
The formula appears to be a homeopathic preparation — ingredients such as Causticum, Graphite, Lycopodium Clavatum, and Sulfur Iodide are classical homeopathic remedies sold at ultra-dilute potencies, which are outside the scope of conventional pharmacological mechanism modeling.

Currently, detailed mechanism of action data is not available. Based on known information, this compound is a homeopathic multi-ingredient mixture; its efficacy in any conventional indication has not been established through regulatory pathways, and mechanistic applicability to new indications cannot be assessed without individual-ingredient decomposition.

Safety Considerations

Please refer to the package insert for safety information.

Note on Arsenic Trioxide: If this formulation contains pharmacologically active (non-homeopathic) concentrations of arsenic trioxide, it would carry significant toxicity concerns including QT prolongation, APL-associated differentiation syndrome, and hepatotoxicity. Clarification of dosing concentration is required before any safety assessment can proceed.

Conclusion and Next Steps

Decision: Hold

Rationale: The pipeline could not identify a DrugBank ID, original indication, or TxGNN prediction for this multi-ingredient homeopathic formula; there is currently no evidence base to support a repurposing hypothesis.

To proceed, the following is needed:

Decompose the formula — evaluate each of the 24 ingredients individually; map each to its own DrugBank ID and run per-ingredient TxGNN predictions
Clarify regulatory identity — determine whether this is a licensed homeopathic product in any jurisdiction (e.g., German HAB, US HPUS) and retrieve its approved indication(s)
Confirm active ingredient concentrations — particularly for Arsenic Trioxide, Potassium Bromide, and Strychnos Nux-Vomica, which carry dose-dependent toxicity and require clear potency/dilution disclosure before safety evaluation
Retrieve MOA data — query DrugBank individually for pharmacologically active components (e.g., Arsenic Trioxide, Berberine from Berberis, Centella Asiatica extracts) to enable mechanism-based analysis
Re-run the TxGNN pipeline on individual active ingredients once DrugBank IDs are confirmed
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.